Research programme: diabetes therapy - Phosphagenics/Baker Heart Research Institute
Latest Information Update: 31 Jan 2007
At a glance
- Originator Baker Medical Research Institute; Phosphagenics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 24 Aug 2005 Preclinical trials in Type-2 diabetes mellitus in Australia (unspecified route)